American Liver Foundation

Hepatitis D Roundtable to Address Unmet Needs of Patients

Retrieved on: 
Thursday, April 21, 2022
Coinfection, Patient, Hepatitis D, Awareness, Liver disease, Hepatitis B, Hepatitis B virus, Twitter, HBV, Research, Hepatitis B Foundation, Caregiver, Hepatitis, ALF, Education, Infection, American Liver Foundation, Blog, HDV, Doctor of Public Health, Solution, Communication, Instagram, Physician, Cirrhosis, Disease, Quality of life, Liver, Liver failure, MPH, Pharmaceutical industry, Vaccine, Facebook

FAIRFIELD, N.J., April 21, 2022 /PRNewswire/ -- The American Liver Foundation (ALF) and Hepatitis B Foundation will join forces with key stakeholders concerned with identifying and addressing the unmet needs of people living with hepatitis D virus (HDV). The virtual Hepatitis D roundtable, to be held on April 21 and 22, will bring together medical experts, patients, and care partners in the hopes of finding solutions to some of the most vexing issues facing people living with HDV.

Key Points: 
  • American Liver Foundation and Hepatitis B Foundation join forces with patients, medical providers and care partners in virtual two-day event
    FAIRFIELD, N.J., April 21, 2022 /PRNewswire/ -- The American Liver Foundation (ALF) and Hepatitis B Foundation will join forces with key stakeholders concerned with identifying and addressing the unmet needs of people living with hepatitis D virus (HDV).
  • "The link between people suffering from hepatitis B and hepatitis D and liver failure has not been well understood," said Lorraine Stiehl, chief executive officer of American Liver Foundation.
  • The American Liver Foundation and Hepatitis B Foundation will jointly publish a report highlighting lessons learned from the roundtable, as a resource for people living with hepatitis D and their providers.
  • For more information about hepatitis D, visit Hepatitis Delta Connect , the Hepatitis B Foundation's program dedicated to HDV.

American Liver Foundation Marathon Runners Hit the Pavement to Fight Liver Disease

Retrieved on: 
Tuesday, April 12, 2022
Cholangiocarcinoma, Portal hypertension, PSC, Awareness, Liver disease, Pain, Liver cancer, American Liver Foundation, COVID-19, National, Research, Boston Athletic Association, Abdomen, ALF, Education, Primary sclerosing cholangitis, Running, Patient, Congenital hepatic fibrosis, Boston Marathon, Friends, Walking, Non-alcoholic fatty liver disease, NAFLD, NEW, History, Parent, Cirrhosis, Partnership, Disease, Liver, Survival, Coffee, Dietary supplement, Animal, Dentistry

NEW YORK, April 12, 2022 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Boston Marathon Official Charity Program for the 2022 Boston Marathon®, which takes place on Monday, April 18th.

Key Points: 
  • Since 1988, the American Liver Foundation Marathon Team has made a dramatic impact on the American Liver Foundation's mission to promote education, advocacy, support services and research for the prevention, treatment, and cure of liver disease.
  • The American Liver Foundation team is made up of novice to experienced runners, most of whom have a connection to liver disease .
  • The American Liver Foundation is the nation's largest non-profit organization focused solely on promoting liver health and disease prevention.
  • The mission of the American Liver Foundation isto promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.

Verantos Announces Breakthrough in Non-alcoholic Steatohepatitis Real-world Evidence

Retrieved on: 
Thursday, March 24, 2022
Non-alcoholic fatty liver disease, Obesity, PALO, Fatty liver disease, American Liver Foundation, Observation, Natural language processing, Multimedia, Research, Standard of care, Health information management, CEO, Intelligence, Prevalence, RWE, NASH, Technology, Liver disease, NAFLD, Virginia Commonwealth University, Chronic liver disease, Patient, Medical imaging, Medical device, Amgen

PALO ALTO, Calif., March 24, 2022 /PRNewswire/ -- Verantos, the market leader in high-validity real-world evidence generation, announced that along with its research partners, the company accomplished a significant step forward in applying advanced real-world evidence approaches to non-alcoholic steatohepatitis (NASH).

Key Points: 
  • PALO ALTO, Calif., March 24, 2022 /PRNewswire/ -- Verantos , the market leader in high-validity real-world evidence generation, announced that along with its research partners, the company accomplished a significant step forward in applying advanced real-world evidence approaches to non-alcoholic steatohepatitis (NASH).
  • Real-world evidence (RWE) aims to learn from routine care to improve the standard of care.
  • "This opens the door to robust research that can benefit patients," stated Dr. Dan Riskin, founder and CEO of Verantos.
  • The Verantos RWE platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for regulatory and reimbursement use.

Medical Fellows and Physicians from Across the U.S. Team Up for Annual Liver Disease Competition

Retrieved on: 
Thursday, March 24, 2022
ALF, American Liver Foundation, Institute of Liver and Biliary Sciences, Transplant, Gastroenterology, CME, Caregiver, Liver, Research, Program, Environment, Internal medicine, Academy, Infection, Liver disease, Physician, Education, Patient, Medicine, Dietary supplement

FAIRFIELD, N.J., March 24, 2022 /PRNewswire/ -- The American Liver Foundation (ALF) will host its annual Academic Debate Madness, a week-long educational competition for medical professionals featuring 28 teams, 60 debaters, and 21 unique topics in liver disease, beginning on Monday, March 28, 2022.

Key Points: 
  • Specialists and fellows in primary care, internal medicine, gastroenterology, hepatology, transplant surgery and infectious disease participate, as do members of allied health fields.
  • "If you are a liver healthcare professional, this is your annual go to event," said Emmanuel Thomas M.D., Ph.D., FAASLD, a National Medical Advisor for American Liver Foundation.
  • The American Liver Foundation is the nation's largest non-profit organization focused solely on promoting liver health and disease prevention.
  • The mission of the American Liver Foundation isto promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.

BioVie Announces Partnership with the American Liver Foundation

Retrieved on: 
Thursday, December 9, 2021
NASH, Population, SEC, Liver disease, CEO, Trial of the century, Alzheimer's disease, Ascites, American Liver Foundation, Cirrhosis, Abdomen, GLOBE, Fast track (FDA), NFB, Hand, Cancer, Neurodegeneration, SOC, Industry, Life, United States Department of Veterans Affairs, Complication, Company, Fatty liver disease, Pharmacokinetics, ALF, Evaluation, Caregiver, Incidence, Insulin resistance, FDA, Institute of Liver and Biliary Sciences, Awareness, Research, Review, Liver, 8-K, TNF, Education, Standard of care, Program, Hepatorenal syndrome, Clinical trial, Survival, NASDAQ, Terlipressin, ERK, Pharmaceutical industry

Our mission is to provide education, advocacy and other support services to everyone whose life is impacted by liver diseases, said Lorraine Stiehl, CEO of the American Liver Foundation.

Key Points: 
  • Our mission is to provide education, advocacy and other support services to everyone whose life is impacted by liver diseases, said Lorraine Stiehl, CEO of the American Liver Foundation.
  • The American Liver Foundation (ALF) is the largest patient advocacy organization devoted to liver diseases.
  • The American Liver Foundation receives contributions and funding from clinical trial and study sponsors.
  • The American Liver Foundation does not evaluate or endorse any clinical trials or studies and is not affiliated with any of the sponsors.

Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH

Retrieved on: 
Tuesday, November 30, 2021
Patient, Private Securities Litigation Reform Act, Security (finance), Liver disease, Government, Doctor of Pharmacy, American Liver Foundation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Plasma protein binding, Genomics, Risk, Response, HEPA, Company, Proteomics, Population, Cyclophilin, Institute of Liver and Biliary Sciences, Lipidomics, Fatty liver disease, Priority review, HDV, Agency, Doctor of Philosophy, Accelerated approval (FDA), U.S. Securities and Exchange Commission, Review, HCV, COVID-19, Program, Biopsy, Metabolomics, Precision medicine, Artificial intelligence, Cirrhosis, HBV, F2, Communication, GLOBE, Adult, Fast Track, NASH, Ill, FDA, Drug development, Failure, NASDAQ, Food, Pharmaceutical industry, Medical device

The FDA Fast Track designation allows sponsors to gain access to expedited drug approval reviews for medical conditions that are serious and potentially life-threatening, and where there is an unmet medical need.

Key Points: 
  • The FDA Fast Track designation allows sponsors to gain access to expedited drug approval reviews for medical conditions that are serious and potentially life-threatening, and where there is an unmet medical need.
  • We are now looking forward to initiating our larger Phase 2b NASH study, called ASCEND-NASH, in biopsy confirmed F2 and F3 NASH subjects in the coming months.
  • As such, we are very pleased to receive the FDAs Fast Track designation and are looking forward to working closely with the Agency as we advance development of CRV431.
  • Additionally, as part of the FDA Fast Track designation for CRV431 in NASH, Hepion will make its expanded access policy publicly available in the coming weeks.

Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020

Retrieved on: 
Monday, November 2, 2020
American Association for the Study of Liver Diseases, Medicine, Health care, American Liver Foundation

The content of the presentation will also be part of a dedicated Key Opinion Leader (KOL) webcast focused on NASH and hosted by Inventiva on November 16, 2020 on the sidelines of the AASLD The Liver Meeting Digital Experience 2020.

Key Points: 
  • The content of the presentation will also be part of a dedicated Key Opinion Leader (KOL) webcast focused on NASH and hosted by Inventiva on November 16, 2020 on the sidelines of the AASLD The Liver Meeting Digital Experience 2020.
  • This event can be followed both live and on-demand on Inventivas website in the Investors Investor Presentations section at: http://inventivapharma.com/investors/investor-presentations/ .
  • AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.
  • AASLD fosters research that leads to improved treatment options for millions of liver disease patients.

Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience™ 2020

Retrieved on: 
Wednesday, October 28, 2020
American Association for the Study of Liver Diseases, Medicine, Health care, American Liver Foundation

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.

Key Points: 
  • AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.
  • AASLD fosters research that leads to improved treatment options for millions of liver disease patients.
  • AASLD advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.
  • Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.

Salix Supports Liver Awareness Month With New Educational Initiatives

Retrieved on: 
Monday, October 5, 2020
Medical specialties, Liver, Anatomy, Hepatology, Chronic liver disease, Liver disease, American Liver Foundation, Hepatic encephalopathy, Primary biliary cholangitis

As part of Salix's support for Liver Awareness Month, the company has launched a new, digital destination, "LiverHEalthNow," which offers tools to support the management of Overt Hepatic Encephalopathy (OHE) in chronic liver disease patients.

Key Points: 
  • As part of Salix's support for Liver Awareness Month, the company has launched a new, digital destination, "LiverHEalthNow," which offers tools to support the management of Overt Hepatic Encephalopathy (OHE) in chronic liver disease patients.
  • Salix's Liver Awareness Month initiatives include:
    A new, online resource designed to support the management of patients suffering from chronic liver disease and OHE.
  • Salix will join the national conversation about OHE through social media, leveraging its Twitter and LinkedIn platforms to galvanize awareness of OHE's prevalence and symptoms.
  • As a corporate council member of the American Liver Foundation (ALF), Salix is a sponsor of The American Debates, The Progression of Liver Disease campaign and Virtual Liver Life Walks.

Less Than a Quarter of U.S. Adults Say They’ve Been Tested for Hepatitis C Despite CDC Recommendations for Universal Testing

Retrieved on: 
Tuesday, July 28, 2020
MEN, Health, Insurance, Finance, Consumer, Other Health, Professional services, Philanthropy, Managed care, Infectious diseases, General Health, Foundation, Women, Seniors, Healthcare-associated infections, Health, Medical specialties, Infectious causes of cancer, RTT, Hepatitis C, Hepatitis, Liver disease, Liver, Viral hepatitis, HCV genotypes, Lincoln Financial Group, American Liver Foundation

The same is true when it comes to HCV, the silent epidemic for which theres a cure.

Key Points: 
  • The same is true when it comes to HCV, the silent epidemic for which theres a cure.
  • Unfortunately, the disease has few noticeable symptoms, which often dont appear for years or decades.
  • To learn more about hepatitis C diagnosis, treatment and support, visit HepC123.org
    To see the full hepatitis C survey conducted by Lincoln, click here .
  • Founded in 1976, the American Liver Foundation is the nations largest patient advocacy organization for people living with liver disease.